Cannabis Science Inc

COLORADO SPRINGS, Colo., Mar 30, 2012 (BUSINESS WIRE) — Cannabis Science, Inc. (CBIS, Trade ) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to announce that Dr. Melamede was featured on NBC Channel 12 News in Arizona yesterday, March 29th, answering medical questions and discussing the new documentary “Chronic Future – Killing Cancer”, which will premier on April 5th, 2012, at the Harkins Theater on Shea and Scottsdale Road in Scottsdale.

The documentary “Chronic Future – Killing Cancer” has been receiving a lot of buzz and potential media coverage by TV channels, news stations and radio stations. The first television news channel to have the pleasure of interviewing Cannabis Science’s own, Dr. Robert Melamede about this documentary, was NBC Channel 12 News. The interview was aired yesterday March 29th at 4:30pm in Arizona. Dr. Melamede answered questions via Skype regarding the effectiveness of medical cannabis, and discussed the documentary, which he himself is featured in as well as Cannabis Science patient’s one and three. Relating to use of medical cannabis and it killing cancer, Dr. Robert Melamede stated, “People are able to experiment on themselves, and are able to do that in a relatively safe manner because of the extremely low toxicity of cannabinoids and the main active ingredients in cannabis.” Also one of the creators of the documentary Henry Miller appeared in studio speaking about why he wanted to show the medical marijuana debate in the documentary.

You can view this interview on the NBC Channel 12 News website, and search “Documentary Claims Hemp Cures Cancer”, to learn more about the documentary and the use and effectiveness of medical cannabis.

The documentary covers everything from the success in the use of medical cannabis with different cancer patients, as well as the unfortunate reality in which the federal government has made it difficult for patients in every state, who need the use of medicinal cannabis for a chronic disease or illness, to attain their medicine without fear.

Cannabis Science is currently waiting to receive confirmation from Henry Miller about numerous other media stations, to promote this must see documentary and provide awareness to everyone about cannabis itself.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

SOURCE: Cannabis Science, Inc.

Cannabis Science, Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO

Robert Kane, 1-561-234-6929
Vice President Investor Relations

Muse Entertainment
Hank Miller, 480-678-7728